×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TRVI – trevi therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TRVI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/11
07:40 pm
trvi
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]
Low
Report
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]
1/11
06:37 pm
trvi
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism [Yahoo! Finance]
Low
Report
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism [Yahoo! Finance]
1/9
08:02 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
1/8
08:23 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
1/8
07:30 am
trvi
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
Low
Report
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
12/23
01:23 pm
trvi
MarketBeat's Top 5 Rated Small-Cap Stocks [Yahoo! Finance]
Low
Report
MarketBeat's Top 5 Rated Small-Cap Stocks [Yahoo! Finance]
12/21
07:42 am
trvi
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change [Yahoo! Finance]
Medium
Report
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change [Yahoo! Finance]
12/19
10:04 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) was given a new $18.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) was given a new $18.00 price target on by analysts at Stifel Nicolaus.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
04:05 pm
trvi
Form 4 Trevi Therapeutics, Inc. For: Jan 08 Filed by: HASTINGS DAVID C
Neutral
Report
Form 4 Trevi Therapeutics, Inc. For: Jan 08 Filed by: HASTINGS DAVID C
1/12
04:03 pm
trvi
Form 3 Trevi Therapeutics, Inc. For: Jan 08 Filed by: HASTINGS DAVID C
Neutral
Report
Form 3 Trevi Therapeutics, Inc. For: Jan 08 Filed by: HASTINGS DAVID C
12/5
08:58 am
trvi
Form 8-K Trevi Therapeutics, Inc. For: Dec 01
Low
Report
Form 8-K Trevi Therapeutics, Inc. For: Dec 01
12/3
04:17 pm
trvi
Form 4 Trevi Therapeutics, Inc. For: Dec 02 Filed by: Galletta Christopher
Low
Report
Form 4 Trevi Therapeutics, Inc. For: Dec 02 Filed by: Galletta Christopher
11/14
04:58 pm
trvi
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Low
Report
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
11/14
04:35 pm
trvi
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: Frazier Life Sciences Public Fund, L.P.
Low
Report
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: Frazier Life Sciences Public Fund, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/31
Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock.
67.9%
3/16 TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE 48.3%
6/18 Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference 12.7%
5/13 Form 3 Trevi Therapeutics, Inc. For: May 07 Filed by: OSHEA WILLIAM J 11.5%
3/16 Trevi Therapeutics up 57% on advancement of key programs [Seeking Alpha] 10.3%
4/13 Form 4 Trevi Therapeutics, Inc. For: Apr 03 Filed by: Behbahani Ali 9.9%
2/25 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.6%
1/15 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.9%
11/14 Form 8-K Trevi Therapeutics, Inc. For: Nov 14 7.9%
8/21 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.6%
3/16 TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE 48.3%
6/18 Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference 12.7%
5/13 Form 3 Trevi Therapeutics, Inc. For: May 07 Filed by: OSHEA WILLIAM J 11.5%
3/16 Trevi Therapeutics up 57% on advancement of key programs [Seeking Alpha] 10.3%
4/13 Form 4 Trevi Therapeutics, Inc. For: Apr 03 Filed by: Behbahani Ali 9.9%
2/25 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.6%
1/15 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.9%
11/14 Form 8-K Trevi Therapeutics, Inc. For: Nov 14 7.9%
8/21 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.6%
TOP News Decliners
5/7
Form S-1/A Trevi Therapeutics, Inc.
-16.9%
10/10 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.8%
3/11 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.8%
8/12 Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments -7.1%
1/31 Form SC 13G Trevi Therapeutics, Inc. Filed by: Lundbeckfond Invest A/S -6.2%
2/13 Form SC 13G Trevi Therapeutics, Inc. Filed by: TPG Group Holdings (SBS) Advisors, Inc. -6.2%
9/19 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.9%
2/20 Trevi Therapeutics to Present at SVB Leerink Healthcare Conference -4.0%
7/2 Form 8-K Trevi Therapeutics, Inc. For: Jun 28 -4.0%
6/25 Trevi Therapeutics (TRVI) Investor Presentation - Slideshow [Seeking Alpha] -3.8%
10/10 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.8%
3/11 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.8%
8/12 Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments -7.1%
1/31 Form SC 13G Trevi Therapeutics, Inc. Filed by: Lundbeckfond Invest A/S -6.2%
2/13 Form SC 13G Trevi Therapeutics, Inc. Filed by: TPG Group Holdings (SBS) Advisors, Inc. -6.2%
9/19 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.9%
2/20 Trevi Therapeutics to Present at SVB Leerink Healthcare Conference -4.0%
7/2 Form 8-K Trevi Therapeutics, Inc. For: Jun 28 -4.0%
6/25 Trevi Therapeutics (TRVI) Investor Presentation - Slideshow [Seeking Alpha] -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: